Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 3
2015 2
2016 2
2017 1
2018 1
2019 2
2020 4
2021 6
2022 10
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Advances and challenges in precision medicine in salivary gland cancer.
Lassche G, van Boxtel W, Ligtenberg MJL, van Engen-van Grunsven ACH, van Herpen CML. Lassche G, et al. Among authors: van engen van grunsven ach. Cancer Treat Rev. 2019 Nov;80:101906. doi: 10.1016/j.ctrv.2019.101906. Epub 2019 Oct 14. Cancer Treat Rev. 2019. PMID: 31644971 Review.
[18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.
de Koster EJ, van Engen-van Grunsven ACH, Bussink J, Frielink C, de Geus-Oei LF, Kusters B, Peters H, Oyen WJG, Vriens D; EFFECTS trial study group. de Koster EJ, et al. Among authors: van engen van grunsven ach. Mol Imaging Biol. 2023 Jun;25(3):483-494. doi: 10.1007/s11307-022-01776-4. Epub 2022 Oct 17. Mol Imaging Biol. 2023. PMID: 36253663 Free PMC article. Clinical Trial.
Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients.
Lassche G, van Helvert S, Eijkelenboom A, Tjan MJH, Jansen EAM, van Cleef PHJ, Verhaegh GW, Kamping EJ, Grünberg K, van Engen-van Grunsven ACH, Ligtenberg MJL, van Herpen CML. Lassche G, et al. Among authors: van engen van grunsven ach. Cancers (Basel). 2022 Aug 27;14(17):4156. doi: 10.3390/cancers14174156. Cancers (Basel). 2022. PMID: 36077692 Free PMC article.
Molecular Diagnostics and [18F]FDG-PET/CT in Indeterminate Thyroid Nodules: Complementing Techniques or Waste of Valuable Resources?
de Koster EJ, Morreau H, Bleumink GS, van Engen-van Grunsven ACH, de Geus-Oei LF, Links TP, Wakelkamp IMMJ, Oyen WJG, Vriens D. de Koster EJ, et al. Among authors: van engen van grunsven ach. Thyroid. 2024 Jan;34(1):41-53. doi: 10.1089/thy.2023.0337. Epub 2023 Dec 28. Thyroid. 2024. PMID: 38009209 Free PMC article. Clinical Trial.
IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.
Crezee T, Tesselaar MH, Jaeger M, Rabold K, Corver WE, Morreau H, Van Engen-Van Grunsven ACH, Smit JWA, Netea-Maier RT, Plantinga TS. Crezee T, et al. Among authors: van engen van grunsven ach. Oncol Lett. 2021 Aug;22(2):590. doi: 10.3892/ol.2021.12851. Epub 2021 Jun 6. Oncol Lett. 2021. PMID: 34149901 Free PMC article.
Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
Lassche G, van Engen-van Grunsven ACH, van Hooij O, Aalders TW, Am Weijers J, Cocco E, Drilon A, Hoischen A, Neveling K, Schalken JA, Verhaegh GW, van Herpen CML. Lassche G, et al. Among authors: van engen van grunsven ach. Oral Oncol. 2023 Feb;137:106297. doi: 10.1016/j.oraloncology.2022.106297. Epub 2023 Jan 5. Oral Oncol. 2023. PMID: 36610231 Free PMC article.
32 results